Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Down 49.3% in February

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the recipient of a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling 15,304 shares, a decline of 49.3% from the February 12th total of 30,190 shares. Based on an average daily trading volume, of 47,528 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the company’s shares are sold short. Approximately 0.2% of the company’s shares are sold short. Based on an average daily trading volume, of 47,528 shares, the short-interest ratio is presently 0.3 days.

Lisata Therapeutics Price Performance

NASDAQ:LSTA remained flat at $5.03 during trading hours on Friday. The company’s stock had a trading volume of 32,551 shares, compared to its average volume of 81,918. The firm has a 50-day moving average price of $3.93 and a 200-day moving average price of $2.83. Lisata Therapeutics has a 1-year low of $1.81 and a 1-year high of $5.07. The firm has a market capitalization of $44.36 million, a PE ratio of -2.63 and a beta of 1.28.

Lisata Therapeutics (NASDAQ:LSTA) last issued its earnings results on Thursday, March 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.41. The firm had revenue of $0.10 million during the quarter. As a group, analysts anticipate that Lisata Therapeutics will post -2.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LSTA. Renaissance Technologies LLC increased its stake in shares of Lisata Therapeutics by 6.1% in the 4th quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock worth $230,000 after purchasing an additional 7,093 shares in the last quarter. Ground Swell Capital LLC lifted its position in Lisata Therapeutics by 64.0% during the fourth quarter. Ground Swell Capital LLC now owns 38,987 shares of the company’s stock valued at $73,000 after purchasing an additional 15,213 shares in the last quarter. CIBC Bancorp USA Inc. bought a new stake in Lisata Therapeutics during the third quarter valued at about $37,000. Finally, Cerity Partners LLC bought a new stake in Lisata Therapeutics during the second quarter valued at about $32,000. Institutional investors own 8.94% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Lisata Therapeutics in a report on Thursday, January 22nd. Brookline Capital Acquisition lowered shares of Lisata Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $23.50.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.